| [1] TorreLA,Bray F,Siegel RL.Global cancer statistics 2012[J].CA Cancer J Clin,2015,65(2):87-108.[2] Villanueva A,Llovet JM.Liver cancer in 2013:Mutational landscape of HCC-the end of the beginning[J].Nat Rev Clin Oncol,2014,11 (2):73-74.[3] Willatt J,Hannawa KK,Ruma JA.Image-guided therapies in the treatment of hepatocellular carcinoma:A multidisciplinary perspective[J].World J Hepatol,2015,7(2):235-244.[4] Ni JY,Xu LF,Wang WD,et al.Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2014,20 (45):17206-17217.[5] Hawkins MA,Dawson LA.Radiation therapy for heapatocellular carcinoma[J].Cancer,2006,106(8):1653-1663.[6] Zeng ZC,Fan J,Tang ZY,et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J].Int J Radiat Oncol Biol Phys,2005,61(2):432-443.[7] Lambert B,VandeWiele C.Treatment of hepatocellular carcinoma by means of radiopharmaceuticals [J].Eur J Nucl Med Mol Imaging,2005,32(8):980-989.[8] Ariel IM,Pack GT.Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy[J].Cancer,1967,20(5):793-804.[9] Blanchard RJ,Grotenhuis I,Lafave JW,et al.Treatment of experimental tumors; utilization of radioactive microspheres[J].Arch Surg,1964, 89:406-410.[10] NeffR,Abdel-Misih R,Khatri J,et al.The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors[J].Cancer Invest, 2008,26(2):173-177.[11] Yan ZP,Lin G,Zhao HY,et al.An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer[J].Cancer,1993,72(11):3210-3215.[12] Sacco R,Mismas V,Marceglia S.Transarterial radioembolization for hepatocellular carcinoma:An update and perspectives[J].World J Gastroenterol,2015,21 (21):6518-6825.[13] Riaz A,Awais R,Salem R.Side effects of yttrium-90 radioembolization[J].Front Onol,2014.doi:10.3389/fonc.2014.00198.[14] Sangro B,Iarrairaegui L,Bilbao JI.Radioembolization for hepatocellular carcinoma[J].J Hepatol, 2012,56(2):464-473.[15] Lewandowski RJ,Kulik LM,Riaz A,et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma:chemoembolization versus radioembolization[J].Am J Transplant,2009,9(8):1920-1928.[16] She WH,Cheung TT,Yau TC,et al.Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection[J].Hepatobiliary Surg Nutr,2014,3 (4):185-193.[17] Vouche M,Kulik L,Atassi R,et al.Radiological-pathological analysis of WHO,RECIST,EASL,mRECIST and DWI:Imaging analysis from a prospective randomized trial of Y90 ± sorafenib[J].Hepatology,2013,58 (5):1655-1666.[18] Kulik L,Vouche M,Koppe S, et al.Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J].J Hepatol,2014,61 (2):309-317.[19] Fujiki M,Aucejo F,Choi M,et al.Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation:where do we stand?[J]. World J Gastroenterol,2014,20 (18):5308-5319.[20] Mazzaferro V,Sposito C,Bhoori S,et al.Yttrium-9 radioembolization for intermediate-advanced hepatocellular carcinoma:a phase 2 study[J].Hepatology,2013,57(5):1826-1837.[21] Hilgard P,Hamami M,Fouly AE,et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:European experience on safety and long-term survival[J].Hepatology,2010,52 (5):1741-1749.[22] Salem R,Lewandowski RJ,Mulcahy MF,et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J].Gastroenterology,2010,138 (1):52-64.[23] Liu D,Fong DY,Chan AC,et al.Hepatocellular carcinoma:surveillance CT schedule after hepatectomy based on risk stratification[J].Radiology,2015,274(1):133-140.[24] Crissien AM,Frenette C.Current management of hepatocellular carcinoma[J].Gastroenterol Hepatol,2014,10(3):153-161.[25] Bruix J,Gores GJ,Mazzaferro V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.[26] Woo HY,Heo J.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis[J].Clin Molecul Hepatol,2015,21 (2 ):115-121.[27] Lambert B,Sturm E,Mertens J,et al.Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma:4 years experience at the Ghent University Hospital[J].Eur J Nucl Med Mol Imaging,2011,38(12):2117-2124.[28] Strigari L,Sciuto R,Rea S,et al.Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres:radiobiologic considerations[J].J Nucl Med,2010,51(9):1377-1385.[29] Andreana L,Isgro G,Marelli L,et al.Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds:Trans-arterial radio-embolisation of HCC[J].Cancer Treat Rev,2012,38 (6):641-649.[30] 王保信,武振明,张 锐,等.联合应用雷替曲塞及表柔比星经肝功脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J].临床肝胆病杂志,2015,31(5):725-728.[31] 祝普利,尹 超,冯建龙.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968. |
